- Home
- MEOH vs DNLI Comparison
MEOH vs DNLI Comparison
Compare MEOH & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MEOH | DNLI |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MEOH | DNLI |
|---|---|---|
| Price | $40.67 | $16.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $47.56 | $32.18 |
| AVG Volume (30 Days) | 410.1K | ★ 1.7M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 40.35 | N/A |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $3,569,374,000.00 | N/A |
| Revenue This Year | $1.99 | N/A |
| Revenue Next Year | $12.55 | $3,973.10 |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.46 | $10.57 |
| 52 Week High | $54.49 | $24.35 |
Technical Indicators
Market Signals| Indicator | MEOH | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 64.75 | 39.89 |
| Support Level | $39.62 | $16.66 |
| Resistance Level | $40.55 | $17.85 |
| Average True Range (ATR) | 0.90 | 0.66 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 91.16 | 19.16 |
Price Performance
Historical ComparisonAbout MEOH Methanex Corporation
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.